Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Multidonor FMT capsules improve symptoms and decrease fecal calprotectin in ulcerative colitis patients while treated - an open-label pilot study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Plasma calprotectin is superior to serum calprotectin as a biomarker of intestinal inflammation in ulcerative Colitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Gastric cancer and gastrin: on the interaction of Helicobacter pylori gastritis and acid inhibitory induced hypergastrinemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The microbiome reflects diagnosis and predicts disease severity in paediatric onset inflammatory bowel disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Systematic review with meta-analyses: does the pathogen matter in post-infectious irritable bowel syndrome?

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Increased abundance of proteobacteria in aggressive Crohn's disease seven years after diagnosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Sepsis-related Organ Failure Assessment Score is a strong predictor of survival in acute-on-chronic liver failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Increased risk of diabetes mellitus five years after an episode of Staphylococcus aureus bacteraemia

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Growing evidence indicates that gut dysbiosis is a factor in the pathogenesis of ulcerative colitis (UC). Fecal microbiota transplantation (FMT) appears to be promising in inducing UC remission, but there are no reports regarding administration using capsules.

METHODS: Seven patients with active UC, aged 27-50 years, were treated with 25 multidonor FMT capsules daily for 50 days as a supplement to their standard treatment in an open-label pilot study. The primary objective was to follow symptoms through the Simple Clinical Colitis Activity Index (SCCAI). Secondary objectives were to follow changes in fecal calprotectin and microbial diversity through fecal samples and quality of life through the Inflammatory Bowel Disease Questionnaire (IBDQ). Participants were followed through regular visits for six months.

RESULTS: From a median of 6 at baseline, the SCCAI of all participants decreased, with median decreases of 5 (p = .001) and 6 (p = .001) after 4 and 8 weeks, respectively. Three of the seven patients had flare-up/relapse of symptoms after the active treatment period. The median F-calprotectin of ≥1800 mg/kg at baseline decreased significantly during the treatment period, but increased again in the follow-up period. The median IBDQ improved at all visits compared to baseline. The fecal microbiota α-diversity did not increase in the study period compared to baseline. All participants completed the treatment and no serious adverse events were reported.

CONCLUSION: Fifty days of daily multidonor FMT capsules temporarily improved symptoms and health-related life quality and decreased F-calprotectin in patients with active UC.

Original languageEnglish
JournalScandinavian Journal of Gastroenterology
Volume54
Issue number3
Pages (from-to)289-296
Number of pages8
ISSN0036-5521
DOIs
Publication statusPublished - Mar 2019

    Research areas

  • Fecal microbiota transplantation, FMT, FMT capsules, microbiota, ulcerative colitis

ID: 56947367